1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceuticals in Spain

Pharmaceuticals in Spain

  • September 2016
  • -
  • MarketLine
  • -
  • 35 pages

Summary
Pharmaceuticals in Spain industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Spain

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Spain

Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Spain pharmaceuticals market with five year forecasts

Synopsis
Essential resource for top-line data and analysis covering the Spain pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
What was the size of the Spain pharmaceuticals market by value in 2015?

What will be the size of the Spain pharmaceuticals market in 2020?

What factors are affecting the strength of competition in the Spain pharmaceuticals market?

How has the market performed over the last five years?

Who are the top competitors in Spain's pharmaceuticals market?

Key Highlights
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2015 annual average exchange rates.

The Spanish pharmaceuticals market had total revenues of $16.1bn in 2015, representing a compound annual growth rate (CAGR) of 0.7% between 2011 and 2015.

Spain's main factor disrupting pharma growth is its continued economic uncertainty. This has reduced public healthcare budgets and simultaneously restricted the spending power of consumers in the private sector as well.

The performance of the market is forecast to accelerate, with an anticipated CAGR of 2.2% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $17.9bn by the end of 2020.

Table Of Contents

Pharmaceuticals in Spain
Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Almirall S.A.
AstraZeneca PLC
GlaxoSmithKline Plc
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: Spain pharmaceuticals market value: $ billion, 2011-15
Table 2: Spain pharmaceuticals market geography segmentation: $ billion, 2015
Table 3: Spain pharmaceuticals market share: % share, by value, 2015
Table 4: Spain pharmaceuticals market value forecast: $ billion, 2015-20
Table 5: Almirall S.A.: key facts
Table 6: Almirall S.A.: key financials ($)
Table 7: Almirall S.A.: key financials (€)
Table 8: Almirall S.A.: key financial ratios
Table 9: AstraZeneca PLC: key facts
Table 10: AstraZeneca PLC: key financials ($)
Table 11: AstraZeneca PLC: key financial ratios
Table 12: GlaxoSmithKline Plc: key facts
Table 13: GlaxoSmithKline Plc: key financials ($)
Table 14: GlaxoSmithKline Plc: key financials (£)
Table 15: GlaxoSmithKline Plc: key financial ratios
Table 16: Spain size of population (million), 2011-15
Table 17: Spain gdp (constant 2005 prices, $ billion), 2011-15
Table 18: Spain gdp (current prices, $ billion), 2011-15
Table 19: Spain inflation, 2011-15
Table 20: Spain consumer price index (absolute), 2011-15
Table 21: Spain exchange rate, 2011-15

List of Figures
Figure 1: Spain pharmaceuticals market value: $ billion, 2011-15
Figure 2: Spain pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 3: Spain pharmaceuticals market share: % share, by value, 2015
Figure 4: Spain pharmaceuticals market value forecast: $ billion, 2015-20
Figure 5: Forces driving competition in the pharmaceuticals market in Spain, 2015
Figure 6: Drivers of buyer power in the pharmaceuticals market in Spain, 2015
Figure 7: Drivers of supplier power in the pharmaceuticals market in Spain, 2015
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2015
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2015
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2015
Figure 11: Almirall S.A.: revenues and profitability
Figure 12: AstraZeneca PLC: revenues and profitability
Figure 13: AstraZeneca PLC: assets and liabilities
Figure 14: GlaxoSmithKline Plc: revenues and profitability
Figure 15: GlaxoSmithKline Plc: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.